Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

2.9K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.9K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

477
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
477
Structure and Function of Platelets01:18

Structure and Function of Platelets

7.1K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
7.1K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

11.1K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
11.1K
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

907
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
907

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of a novel KMT2A/GIMAP8 gene fusion in a pediatric patient with acute undifferentiated leukemia.

Genes, chromosomes & cancer·2020
Same journal

2025 Scholars' Research Symposium Abstract: Influence of Disability Education, Panel Discussion on Comfort and Knowledge of Healthcare Providers in South Dakota.

South Dakota medicine : the journal of the South Dakota State Medical Association·2025
Same journal

2025 Scholars' Research Symposium Abstract: Improving Interactions During Medical Interpretation: An Educational Module for Medical Students.

South Dakota medicine : the journal of the South Dakota State Medical Association·2025
Same journal

2025 Scholars' Research Symposium Abstract: Walk With Ease Benefiting South Dakota.

South Dakota medicine : the journal of the South Dakota State Medical Association·2025
Same journal

2025 Scholars' Research Symposium Abstract: Ultrasonographic Accuracy in Rural vs Urban Counties.

South Dakota medicine : the journal of the South Dakota State Medical Association·2025
Same journal

2025 Scholars' Research Symposium Abstract: Minimizing Grief and Loss Through Advanced Care Planning.

South Dakota medicine : the journal of the South Dakota State Medical Association·2025
Same journal

2025 Scholars' Research Symposium Abstract: Food Security During Pregnancy and Adverse Birth Outcomes.

South Dakota medicine : the journal of the South Dakota State Medical Association·2025
See all related articles

Related Experiment Video

Updated: Apr 20, 2026

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

8.3K

Immune thrombocytopenia.

George M Maher

    South Dakota Medicine : the Journal of the South Dakota State Medical Association
    |November 27, 2014
    PubMed
    Summary
    This summary is machine-generated.

    Childhood immune thrombocytopenia (ITP) is typically mild, diagnosed clinically, and treated with options like IVIG or steroids. While rare, serious complications like intracranial hemorrhage can occur.

    More Related Videos

    Purification of Platelets from Mouse Blood
    05:41

    Purification of Platelets from Mouse Blood

    Published on: May 7, 2019

    24.1K
    Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
    09:46

    Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

    Published on: December 27, 2017

    20.8K

    Related Experiment Videos

    Last Updated: Apr 20, 2026

    A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
    04:32

    A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

    Published on: June 5, 2019

    8.3K
    Purification of Platelets from Mouse Blood
    05:41

    Purification of Platelets from Mouse Blood

    Published on: May 7, 2019

    24.1K
    Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
    09:46

    Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

    Published on: December 27, 2017

    20.8K

    Area of Science:

    • Pediatric Hematology
    • Immunology
    • Autoimmune Disorders

    Background:

    • Immune thrombocytopenia (ITP) in children is an autoimmune condition causing low platelet counts.
    • It typically presents with bruising and petechiae in otherwise healthy children.
    • Diagnosis relies heavily on clinical presentation, minimizing extensive lab work.

    Purpose of the Study:

    • To review the diagnosis and management of childhood ITP.
    • To outline current treatment options and their indications.
    • To discuss potential complications and future research directions.

    Main Methods:

    • Clinical review of immune thrombocytopenia in pediatric patients.
    • Summary of diagnostic criteria and laboratory investigations.
    • Overview of available therapeutic modalities and their efficacy.

    Main Results:

    • ITP is generally benign with clinical diagnosis being key.
    • Treatment indications are variable, focusing on bleeding, anxiety, and quality of life.
    • Common treatments include IVIG, steroids, and WinRho (anti-D), effectively increasing platelet counts.

    Conclusions:

    • Childhood ITP is usually self-limiting, with diagnosis primarily clinical.
    • Treatment decisions are individualized based on symptoms and impact on quality of life.
    • Further research into molecular targets may offer novel therapeutic strategies for ITP.